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Summary. The mouse IgG2a monoclonal antibody 
(MoAb) 345.134S, secreted by a hybridoma derived 
from a mouse immunized with cultured human 
melanoma cells, reacts with an 85,000-dalton glyco- 
polypeptide which is disulfide-bridged to a 30,O00-dal- 
ton polypeptide having little if any covalently attached 
carbohydrate. The 115,000-dalton complex is periph- 
eral rather than integral in its association with the 
plasma cell membrane. Indirect immunofluorescence 
of cryostat thin sections of human tissues with the 
MoAb 345.134S showed (1) strong staining of the 
sebaceous glands and basal layer of normal hyper- 
pigmented skin; (2) weak staining of the basal layer of 
normal pigmented skin and epithelial cells of the 
gastrointestinal tract, parotid, renal proximal tubules, 
thyroid, and urinary bladder; and (3) no staining of 
melanocytes, mammary gland, lung, brain cortex, or 
liver. The staining pattern of tissues from a 
20-week-old fetus is similar to that of tissues from 
adults. The MoAb 345.134S stained some cases of 
virtually all tumors tested, including some derived 
from normal tissues non-reactive with the antibody; 
intensity of staining of tumors was in general much 
greater than in normal tissues. The expression of the 
antigen detected by MoAb 345.134S in a panel of 
cultured human tumor cells did not correlate with the 
expression of other tumor-associated antigens or with 
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HLA-A,B or 1a-like antigens. The MoAb 345.134S 
can mediate complement- and cell-dependent lysis of 
cultured human tumor cells. The lack of correlation 
between the extent of immune lysis and the expression 
of the antigen detected by MoAb 345.134S as well as 
the effect of puromycin on antibody-mediated cell-de- 
pendent lysis indicated that factors other than antigen 
density play a significant role in the outcome of 
immune lytic reactions mediated by this monoclonal 
antibody. 
Introduction 
The production of monoclonal antibodies has greatly 
facilitated the analysis of the antigenic profile of 
human tumor cells. These studies will eventually 
identify markers that will be useful in the develop- 
ment of immunodiagnostic and immunotherapeutic 
approaches to malignant diseases and will contribute 
to our understanding of the abnormal behavior of 
tumor cells. Monoclonal antibodies have been exten- 
sively applied in the analysis of human melanoma 
cells, and through the efforts of several investigators a 
variety of antigens have been identified which are 
expressed by melanoma cells [5, 6, 9-11,  16, 22, 29, 
31] but are not detectable on melanocytes [6, 9, 22, 
29, 31]; these antigens are referred to as melano- 
ma-associated antigens (MAA). We have developed 
several monoclonal antibodies to human melanoma 
cells; in previous studies we have analyzed mono- 
clonal antibodies to a high-molecular-weight plasma 
membrane-bound MAA and to a cytoplasmic MAA 
[22, 29]. In this study we characterize the MoAb 
345.134S, which defines a membrane-bound glyco- 
protein with serological and structural properties 
distinct from those of other membrane-bound glyco- 
proteins identified on human melanoma cells with 
monoclonal antibodies. Specifically, we will describe: 
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(1) the structure of the target antigen; (2) the distri- 
bution of the antigen in normal and malignant tissues; 
and (3) the expression of the antigen on cultured cells 
and its ability to function as a target of immune 
lysis. 
Materials and Methods 
Preparation of Monoclonal Antibodies (MoAb). Splenocytes from 
a BALB/e mouse immunized with cultured melanoma cells Colo38 
were fused with the routine myeloma line Sp 2/0-Ag 14 according to 
the hybridoma procedure described elsewhere [10, 11]. The 
hybridoma secreting MoAb 345.134S, selected by its strong 
reactivity with a panel of cultured cells, has been subcloned twice 
and has been propagated in vitro and in vivo for at least 1 year. 
Immunodiffusion analysis with rabbit anti-mouse Ig antisera 
(Litton Bionetics, Kensington, MD, USA) has shown that the 
MoAb 345.134S is of the IgG2a subclass. The monoelonal 
antibodies Q5/13 to human Ia-like antigens [25], NAMB-1 to 
human flz-microglobulin (fl2-~t) [23], 225.28S to a high-molecu- 
lar-weight MAA [29], and 376.96S to a 94K tumor-associated 
antigen [30] have been described in the indicated references. The 
MoAb W6/32 reactive with the heavy chain of HLA-A,B,C 
antigens [24] was obtained commercially (Accurate Chemical Co., 
Hicksville, NY USA). 
Human Cells. Cells in long-term culture were maintained in RPMI 
1640 medium containing 10% calf serum. Peripheral blood 
lymphocytes (PBL) and leukemic cells were isolated from 
heparinized blood by differential centrifugation on Ficoll-Hypaque 
and then separated into T and B cell populations by nylon wool 
filtration [14]. Peripheral blood monocytes were obtained by 
adherence to plastic in a T75 flask (Falcon Plastics, Cockeysville, 
MD, USA) at 37 ° C for 30 min [14]. Granulocytes were prepared 
from heparinized blood as described by Boyum [3]. 
Melanoma cells in log phase (5 x 105/ml) were cultured with 
500-2,000 IU/ml partially purified human leukocyte interferon (a 
generous gift of Dr. K. Cantell, Central Public Health Center, 
Helsinki, Finland) or with 1 -5  ~tg puromycin/ml (Sigma, St. Louis, 
MO, USA) for 16 h at 37 ° C. The cells were then washed three 
times with minimum essential medium and then used in the 
antibody-dependent cell-mediated cytotoxicity (ADCC) assay. 
The interferon treatment did not affect cell viability or growth, and 
the effect of puromycin on protein synthesis was monitored by 
incorporation of 3H-proline. 
Tissue Specimens. Tissues were obtained surgically from untreated 
patients and from patients undergoing different therapeutic 
regimens. Normal tissues were obtained from surgically removed 
neoplastic lesions. Tissue specimens were snap-frozen in liquid 
nitrogen and two consecutive cryostat sections of 4 ~t thickness 
were obtained from each frozen tissue: one section was stained 
with toluidine blue (0.1% in phosphate-buffered saline), while the 
other was fixed for 10 min in cold absolute acetone and then used in 
the indirect immunofluorescence (IIF) test. Absolute acetone was 
chosen over other fixatives because it retained the most detail after 
fluorescent staining. 
Radiolabelling, Indirect Immunoprecipitation and Sodium Dodecyl 
Sulfate Polyacrylamide Gel Electrophoresis (SDS-PA GE). Human 
melanoma cells were intrinsically radiolabelled with 3H-glucos- 
amine D-[6-3H(N)] 30 mCi/mmole (New England Nuclear, Bos- 
ton, MA, USA) according to the method of Duksin and Bornstein 
[7] or were surface-labelled with 125I (Amersham, Arlington 
Heights IL, USA) by the Iodogen method of Salisbury and 
Graham [27]. Labelled cells were extracted with 10 volumes of 
nonidet P40 detergent (1.0% in phosphate-buffered saline) 
containing 10 ~tm phenylmethylsulfonylfluoride by rotation for 
30 min at 4 ° C. The extract was cleared by centrifugation at 7,000 g 
and stored at -20  ° C. Cell extracts performed with 3 M KCI or with 
urea were performed as described for NP40 and dialyzed against 
phosphate-buffered saline prior to use. Indirect immunoprecipi- 
ration was performed as described previously [1], except that 
protein A-Sepharose 4B (Pharmacia) was used in place of the 
formalin-fixed bacteria, and pre-clearing of the NP40 detergent cell 
extract was not necessary. Briefly, 10 ~tl packed protein A 
Sepharose was mixed with 5 × 10 6 cpm 125I-labelled cell extract 
and diluted to 0.5 ml with NET buffer (50 mM Tris, 150 mM NaC1, 
5 mM EDTA, 1 mg bovine serum albumin/ml, pH 7.4). After 
rotation for 2 h at 4 ° C, the Sepharose was washed eight times with 
NET buffer and then twice with phosphate-buffered saline. SDS 
sample buffer was added (100 ~) [18] and the Sepharose was 
boiled at 100 ° C for 2 rain prior to loading on an SDS-polyacryl- 
amide gel. SDS-PAGE was performed in 80 x 1.5 mm slab gels 
containing an acrylamide gradient of 5%-12.5% and the SDS 
buffer system of Laemmli [18]. The gels containing 3H-glucos- 
amine-labelled antigens were processed for fluorography as 
described by Bonner and Laskey [2] while ~25I-labelled antigens 
were autoradiographed at -70  ° C. Rabbit phosporylase a (94,000), 
bovine serum albumin (68,000), ovalbumin (44,000), carbonic 
anhydrase (29,000), and whale myoglobin (17,000) were used as 
molecular weight standards. 
Binding Assays and Cell- and Complement-dependent Cytotoxicity 
Assays. The IIF test was performed by a standard procedure 
described previously [21]. A distinct bright green fluorescent 
staining of the plasma membrane was used as a criterion of positive 
reactions of tissue sections with monoclonal antibodies. Unreactive 
tissue sections were tested further with concentrated (20 ~tg/ml) 
and diluted (0.5 ~tg/ml) solutions of the monoclonal antibody to 
avoid false-negative reactions attributable to either a low concen- 
tration of the monoclonal antibody or to a prozone-like effect [19]. 
The specificity of fluorescent staining was controlled by testing 
tissue sections with myeloma protein secreted by the murine 
myeloma cells P3-X63-Ag8 or with culture supernatants of the 
hybridomas 345.134S from which the monoclonal antibodies had 
been removed by adsorption at 4 ° C with one volume of cultured 
human melanoma cells (MI0). The efficiency of adsorption was 
confirmed by the failure of the adsorbed culture supernatant to 
stain cultured human melanoma cells. 
The 125I-SPA radioimmunometric assay was performed in 
microtiter plates as described elsewhere [23]. The complement-de- 
pendent microcytotoxic test was performed as an eosin exclusion 
test, rabbit serum being used as the complement source [8]. 
The ADCC assay was performed in 96-well microtiter plates 
(Cooke Laboratory Products, Alexandria, VA, USA) as described 
previously [13]. The percentage of specific 51Cr release from the 
cells was used as a measure of lysis and was calculated as 
follows: 
% ADCC = ( A - B )  - (C-B)  × 100, 
(T-B)  - (C-B)  
where A = mean cpm of test samples, B = mean clam of counter 
background, C = mean cpm of antibody free control in the 
presence of effector cells, and T = mean cpm of total amount of 
51Cr incorporated into the target cells. All test combinations were 
performed in triplicate with spontaneous or background leakage of 
51Cr from the target cells ranging from 13% to 21% of the total 
incorporated radiolabel. 
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Fig. 1. Immunoprecipitation and SDS-PAGE 
analysis of the antigenic structures detected by 
MoAb 345.134S, NP40 extracts of 
3H-glucosamine-labelled or 125Iodine 
surface-labelled Colo 38 melanoma ceils were 
immunoprecipitated with MoAb 345.134S bound 
to Sepharose 4B. The labelled antigens were 
eluted with SDS sample buffer either with or 
without 2% 2-mercaptoethanol and then 
electrophoresed on an SDS-polyacrylamide slab 
gel. The gel was processed by fluorography 
and then exposed to Kodak XR-OMAT film 
Results 
Structural Profile of the Antigen Identified 
by the MoAb 345.134S 
Indirect immunoprecipitation of an NP40 extract of 
3H-glucosamine-labelled melanoma cells Bw5 and 
Colo38 with the MoAb 345.134S and SDS-PAGE 
analysis under reducing conditions (2% 2-mercapto- 
ethanol) revealed a major component with the 
apparent molecular weight of 85,000 (85K) daltons 
and a minor component of 115K daltons (Fig. 1). In 
contrast, when the immunoprecipitate was electro- 
phoresed under non-reducing conditions, only a 
single molecule of 115K daltons was observed. 
Indirect immunoprecipitation of NP40 extracts of 
125I-surface-labelled melanoma cells Colo38 with the 
MoAb 345.134S and SDS-PAGE analysis under 
reducing conditions showed two components, one 
with the apparent molecular weight of 85K daltons 
and the other one with the apparent molecular weight 
of 30K daltons. When the immunoprecipitate was 
electrophoresed under non-reducing conditions, the 
30K-dalton molecule and most of the 85K-dalton 
molecules disappeared and a new structure was seen, 
with the approximate molecular weight of l15K 
daltons. Similar SDS-PAGE results were seen with 
the prostate carcinoma cells H494 and Du 145 (data 
not shown). Thus, these results indicate that the 
structure detected by the monoclonal antibody is 
composed of an 85K-dalton glycopolypeptide linked 
by disulfide bridges with a 30K-dalton polypeptide 
carrying little or no carbohydrate. 
This ll5K-dalton antigen appears to be periph- 
eral rather than integral to the plasma membrane 
since it is readily solubilized under mildly denaturing 
conditions (10 mM phosphate buffer, 3 M KCI, 0.1 M 
urea) and in the absence of detergents (data not 
shown). 
Reactivity of MoAb 345.134S with Surgically 
Removed Normal and Malignant Tissues 
and with Hematopoietic Cells 
Representative patterns of IIF staining of four 
cryostat sections of surgically removed tissues with 
the MoAb 345.134S are shown in Figs. 2 and 3. The 
results have been organized in Table 1 by using the 
criterion of whether normal tissues are reactive or 
unreactive with the monoclonal antibody. The fol- 
lowing points are noteworthy: (a) the reactivity 
pattern of normal tissues with the MoAb 345.134S 
does not correlate with their embryological origin; 
(b) the majority of positive normal tissues gave a 
weak staining which could be detected only by 
examining tissue sections with an oil immersion 
objective, except for the plasma membrane of the 
epithelium of sebaceous glands (Fig. 2) and the basal 
layer of hyperpigmented skin (i.e., mammary areola 
and perineum), both of which were brightly stained. 
It should be noted that the weak fluorescence is 
specific since no staining occurred when the antibody 
solution was absorbed with cultured melanoma cells. 
Normal pigmented skin showed faint staining in 
limited areas of the basal cell layer. The nature of the 
cells in the basal cell layer was not identified; these 
cells are not likely to be melanocytes since the MoAb 
345.134S did not stain melanocytes in other areas of 
skin from either Negro or Caucasian donors; (c)in 
Fig. 2. a - d  Indirect immunofluorescence with the MoAb 345.134S on cryostat sections of adult kidney proximal tubules (a), kidney 
papillary adenocarcinoma (b), adult skin sebaceous glands (e), and skin squamous cell carcinoma (d). The a r r o w  (a) shows staining of the 
basal portion of the cytoplasm of tubular epithelial cells; de (d) refers to dermis, a × 640; b × 1,000; c and d × 400 
Fig, 3. a - d  Indirect immunofluorescence with the MoAb 345.134S on cryostat sections of lung adenocarcinoma (a), intradermal nevus (b), 
primary nodular melanoma (e), and metastatic melanoma (d). Staining is observed at the plasma membrane of these lesions, a, e, and 
d x 400; b x 1,000 
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Table 1. Reactivity of MoAb 345.134S with normal adult and tumor tissues assessed by indirect immunofluorescence a 
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Group Normal tissues Reactivity Tumors No. positive/ 
no. tested 
Group 1 Melanocytes Negative Melanoma 21/25 
Mammary gland Negative Breast adenocarcinoma 9/15 
Lung Negative Lung adenocarcinoma, squamous cell 4/5 
carcinoma, small cell carcinoma 
Brain cortex Negative Mixed brain tumors 1/10 
Liver Negative Liver adenocarcinoma 0/2 
Group 2 Skin 
Pigmented (epithelium of Positive Skin basal cell and squamous 7/7 
sebaceous glands and basal layer) cell carcinoma 
Non-pigmented (basal cell layer) Positive 
(weak) b 
Gastrointestinal tract Positive Gastric and colonic 7/13 
(weak)  adenocarcinoma (weak) 
Urinary bladder Positive Urinary bladder transitional cell 2/3 
(weak)  carcinoma 
Renal proximal tubules Positive Wilms' adenocarcinoma 1/3 
Parotid Positive Parotid mixed cell type 1/2 
(weak) tumor and Warthin's tumor 
Thyroid Positive Thyroid adenocarcinoma 1/2 
(weak) 
a Cryostat sections were used as substrates for antibodies 
b Required oil immersion objective to visualize staining 
Table 2. Reactivity of a panel of human cell lines in a 125I radioimmunometric binding assay with monoclonal antibodies to cell-surface 
markers 
Cell line cpm 125I-SpA bound 
MoAb 345.134S MoAb 376.96S MoAb 225.28S MoAb W6/32 MoAb NAMB-1 MoAb Q5/13 
(anti-85K/30K) (anti-94K) (anti-280K/>440K) (anti-HLA-A,B,C) (anti-fl2-~) (anti-Ia-like) 
Melanoma 
Colo38 9,400 5,000 33,000 11,100 23,000 13,600 
M14 30,000 9,500 15,800 14,000 21,000 1,000 
M21 10,000 2,300 38,500 9,500 16,800 3,300 
Carcinoma 
Mano 18,300 8,300 < 500 5,100 10,000 < 500 
(urinary 
bladder) 
D98 18,000 <500 < 500 1,000 4,700 < 500 
(cervix) 
DU 145 8,000 4,000 < 500 2,600 NT a < 500 
(prostate) 
Lymphoid 
1301 5,700 <500 < 500 12,000 14,500 < 500 
(W cell) 
Raji 4,700 <500 < 500 4,500 NT 8,500 
(B cell) 
Wil-2 6,200 <500 < 500 10,300 NT 20,000 
(B cell) 
aNT = not tested 
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Table 3. Reactivity of the MoAb 345.134S with cultured human 
cells in binding and lytic assays 
Cell line 12SI-Binding Complement- ADCC 





Bw5 25,000 1 x 105 18.3 
Colo38 12,000 1 x 105 35.4 
M21 8,500 1 x 105 15.4 
Carcinoma 
MANO (bladder)iS,300 2 x 103 20.4 
T24 (bladder) 16,000 1 x 104 ND 
B -lymphoid 
Daudi 4,000 1 x 105 10.6 
Raji 4,700 1 x 105 41.3 
WI-L2 6,200 1 x 105 40.6 
T-lymphoid 
1301 5,700 1 x 105 15.5 
Myeloid 
K562 7,000 1 x 105 42.9 
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Fig. 4. a and b Effect of puromycin and interferon on cell-de- 
pendent lysis mediated by MoAb 345.134S. Microtiter plates (each 
with 96 wells) containing 4 x 10351Cr-labelled melanoma M21 cells 
previously treated for 18 h with puromycin 1 pxg/ml ( A - A )  and 
0.1 ~g/ml ([2]-D) or with human leukocyte interferon 1,000 IU/ml 
( A - A )  and 500IU/ml ( I - B )  were incubated with MoAb 
345.134S prior to addition of murine C3H/HeN splenocytes. 
Melanoma cells incubated in medium alone (open and closed 
circles) were used as controls. After 18 h incubation at 37 ° C, the 
supernates were harvested and counted in a gamma counter, after 
which the % 51Cr release was determined as described in Materials 
and Methods 
kidneys, the staining was limited to the plasma 
membrane and the cytoplasm of the epithelium of 
proximal tubules; (d) the reactivity pattern of tissues 
from a 20-week-old fetus is similar to that of normal 
adult tissues; (e) although normal melanocytes in 
sections of normal pigmented and hyperpigmented 
skin were unreactive with the MoAb 345.134S, the 
majority of intradermal (4 out of 6 cases) and 
compound (7 out of 8 cases) nevic cells exhibited 
plasma membrane fluorescence, while six blue nevi 
were unreactive; (f)all the types of tumors tested 
with the exception of liver adenocarcinomas reacted 
strongly with the MoAb 345.134S. However, there 
were some cases within each tumor group that were 
negative. 
In addition to tissue sections, the MoAb 345.134S 
also reacted with T and B lymphocytes, monocytes, 
and granulocytes from the peripheral blood of 
healthy donors and with chronic lymphocytic and 
acute myelogenous leukemic cells in the lzsI-binding 
assay; on the other hand, human erythrocytes were 
unreactive with the monoclonal antibody. 
Lytic Activity of the MoAb 345.134S 
in Complement- and Cell-dependent Cytotoxicity 
of Cultured Human Cells 
The MoAb 345.134S reacts in the 125I-SPA radioim- 
munometric assay with a variety of cell lines which 
include melanoma, carcinoma and lymphoid cell 
types. There is no relationship between the level of 
expression of the antigenic determinant recognized 
by the MoAb 345.134S and other surface markers 
tested (Table 2), i.e., HLA-A,B antigens, Ia-like 
antigens, a 94K glycoprotein recognized by the 
MoAb 376.96S, and a high, molecular-weight glyco- 
protein recognized by the MoAb 225.28S. Further- 
more, the reactivity of the MoAb 345.134S with the 
cell lines Daudi and with our K562 cells, both of 
which lack /32-# [23, 32], is in agreement with 
immunochemical evidence that the structure detected 
by MoAb 345.134S in the SpA-radioimmunometric 
assay is not associated with/32- # and does not require 
/32-# for its expression. The level of antigen detectable 
on melanoma cells with the MoAb 345.134S is not 
affected by treatment with human leukocyte inter- 
feron (500-2,000 IU/ml), but is reduced by treatment 
with puromycin (5 ~g/ml) (data not shown). The 
MoAb 345.134S can mediate complement- and 
cell-dependent lysis of cultured human cells (Table 
3). The degree of lysis in both assays does not show a 
relationship with the extent of binding of the MoAb 
345.134S to the target cells. Furthermore, cultured 
cells display an increased susceptibility to cell-de- 
pendent lysis mediated by the MoAb 345.134S 
following treatment with doses of puromycin 
(1 #g/ml) which do not affect the level of expression 
of the target antigen (Fig. 4). On the other hand, no 
change in the extent of cell-dependent lysis occurs 
when melanoma cells have been treated with inter- 
feron (Fig. 4). 
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Discussion 
Immunochemical analysis of the specificity of the 
MoAb 345.134S has shown that it identifies a 
two-chain structure composed of an 85K-dalton 
glycopolypeptide disulfide-bridged to a 30K-dalton 
polypeptide having little if any covalently attached 
carbohydrate. It is not yet known whether one or 
both chains carry the antigenic determinant detected 
by MoAb 345.134S. Solubilization under various 
conditions showed that the antigen detected by 
MoAb 345.134S is peripheral rather than integral in 
its association with the plasma membrane. 
The MoAb 345.134S was tested with human cell 
lines in a binding assay and with a large variety of 
surgically removed normal and malignant tissues in 
indirect immunofluorescence; the latter assay was 
preferred to adsorption since it allows identification 
of the reactive cells. Furthermore, the ability of 
MoAb 345.134S to immunoprecipitate the corre- 
sponding antigen suggests that it is of high affinity and 
therefore unlikely to cause binding negative/adsorp- 
tion positive reactions, which have been reported for 
certain monoclonal antibodies [6]. Results of this 
extensive serological analysis of MoAb 345.134S 
show the presence of the antigen in epithelial cells of 
certain normal fetal and adult tissues and in a large 
variety of human tumors. In general, the intensity of 
staining is much stronger for tumor lesions than for 
their corresponding normal tissues, suggesting that 
malignant transformation of cells is associated with 
increased synthesis and/or reduced shedding of this 
antigen. A variable number of biopsies within each 
tumor group did not react with MoAb 345.134S. 
Whether this finding reflects polymorphism of the 
antigenic determinant defined by the MoAb 345.134S 
or lack of the antigenic structure in certain tumors is, 
however, presently unknown. Also, the clinical 
significance of this differential reactivity of tumors 
with the MoAb 345.134S cannot be assessed at this 
time since the number of cases tested is too low and 
the clinical information is insufficient to draw any 
firm conclusions. 
The antigen detected by MoAb 345.134S appears 
to be different in its tissue distribution and molecular 
profile from the several other glycoproteins which 
have been identified on human cell lines. Some of the 
most relevant antigens will be compared here. Thus, 
it is different from the 90K-dalton glycoprotein 
described by Judd et al. [15], since this antigen is 
expressed on dividing cells but is absent from 
non-dividing cells and monocytes and the molecule 
exists as a dimer of 200K daltons in its native state. It 
is also different from the 94K-dalton antigen iden- 
tified by our MoAb 376.96S [30], the 95K-dalton 
Antigen 165 
antigen described by Dippold et al. [6], and the 
97K-dalton antigen described by Woodbury et al. 
[31], since they are single-chain structures and they 
are mostly restricted to melanomas and carcinomas. 
The 85K-dalton glycoprotein detected by MoAb 
345.134S is probably different from a 95K-dalton 
glycoprotein isolated from Molt 4 cells [26], since the 
latter is one of the major glycoproteins synthesized by 
these cells while our experience suggests that the 85K 
glycoprotein is not so well represented on these cells. 
Finally, the 85K-dalton glycoprotein is distinct in 
tissue distribution from the common ALL antigen 
described by Sutherland et al. [28] and from the 
100K-dalton glycoprotein found in a variety of 
different tumors by Bramwell and Harris [4]. 
The MoAb 345.134S can mediate complement- 
and cell-dependent lysis of human tumor cells. The 
extent of lysis does not correlate with the level of 
expression of the antigenic determinant recognized 
by this monoclonal antibody, indicating that other 
variables besides antigen density play a significant 
role in the outcome of immune lytic reactions. This 
conclusion is also supported by the finding that 
melanoma cells treated with low doses of puromycin 
increase in susceptibility to cell-dependent lysis 
mediated by the MoAb 345.134S, although the level 
of cell surface target antigen remains unchanged. The 
amount of antigen detectable by MoAb 345.134S on 
melanoma cells was also unaffected by doses of 
interferon that result in increased levels of 
HLA-A,B,C antigens [12]. This result deserves some 
comment in view of the reported beneficial effects of 
interferon on the clinical course of a limited number 
of melanoma patients [17]. Our experience with 
monoclonal antibodies to a high-molecular-weight 
MAA [12] as well as the results here with MoAb 
345.134S indicate that the level of expression of 
tumor-associated antigens as well as the susceptibility 
of melanoma cells to immune lysis mediated by 
monoclonal antibodies to these structures are not 
increased by interferon treatment. These data suggest 
that if immunological factors play any role in t h e  
reported therapeutic effects of interferon on mela- 
noma, they occur by routes other than increased 
expression of tumor-associated antigens, at least 
those identified by the monoclonal antibodies we 
have developed. 
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